<DOC>
	<DOCNO>NCT01348763</DOCNO>
	<brief_summary>This phase I , open label , prospective , two phase pharmacokinetic study . Subjects currently attend HIV care St. Mary 's Hospital , London eligible . The study describe steady state pharmacokinetic parameter short term safety maraviroc/darunavir/ritonavir dose 150/800/100 mg daily without tenofovir/emtricitabine 245/200 mg daily HIV-1 infected subject . Fifteen HIV-1 infected subject recruit . Eligible subject currently receive antiretroviral therapy comprising : - tenofovir/emtricitabine 245/200 mg daily plus - darunavir/ritonavir 800/100 mg daily On day 1 , subject modify current antiretroviral therapy following : - tenofovir/emtricitabine 245/200 mg daily plus - darunavir/ritonavir 800/100 mg daily plus - maraviroc 150 mg daily On day 10 subject undergo intensive pharmacokinetic visit . On day 11 , subject modify current antiretroviral therapy following : - darunavir/ritonavir 800/100 mg daily plus - maraviroc 150 mg daily ( i.e . tenofovir/emtricitabine discontinue ) On day 20 subject undergo intensive pharmacokinetic visit . Following completion study phase , subject recommence usual antiretroviral treatment regimen attend study follow visit .</brief_summary>
	<brief_title>The Maraviroc Darunavir/Ritonavir Once Daily Pharmacokinetic Study</brief_title>
	<detailed_description />
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<criteria>HIV1 infect male female sign informed consent plasma HIV RNA &lt; 50 copies/mL screen least one occasion last 3 month currently receive antiretroviral regimen comprise : tenofovir 245 mg daily , emtricitabine 200 mg daily , darunavir 800 mg daily ritonavir 100 mg daily previous protease inhibitor resistance document HIV1 genotypic resistance test HIV resistance test available Between 18 65 year age , inclusive subject good health upon medical history , physical exam , laboratory test BMI equal 18 32 Female subject heterosexually active childbearing potential ( i.e. , surgically sterile least two year post menopausal ) must practice contraception follow screen 8 week completion study : barrier contraceptive ( condom OR diaphragm PLUS spermicide ) oral , implant injectable hormonal contraceptive PLUS barrier contraceptive IUD /IUS PLUS barrier contraceptive Female subject childbearing potential must negative urine pregnancy test . Male subject heterosexually active must use two form barrier contraception ( e.g. , condom spermicide ) heterosexual intercourse , screen completion study . Have serologic evidence active HBV infection evidence negative hepatitis B surface antigen serologic evidence hepatitis C virus infection evidence negative HCV antibody screen . Have screen laboratory result ( haematology chemistry fall within normal range central laboratory 's reference range unless result determine Investigator clinical significance CCR5 tropic HIV virus base genotypic tropism assay either store plasma sample available fresh plasma current alcohol abuse drug dependence positive urine drug abuse screen pregnancy active opportunistic infection significant comorbidities current disallow concomitant medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2011</verification_date>
</DOC>